Want to see UNCY full AI Analyst Report?
UNCY Stock Chart & Stats
$5.47
$0.03(0.56%)
At close: 4:00 PM EDT
$5.47
$0.03(0.56%)
Day’s Range― - ―
52-Week Range$3.71 - $8.74
Previous CloseN/A
Volume52.73K
Average Volume (3M)749.18K
Market Cap
$143.73M
Enterprise Value$65.55
Total Cash (Recent Filing)$61.42M
Total Debt (Recent Filing)$671.00K
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Nov 18, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding27,855,257
10 Day Avg. Volume637,818
30 Day Avg. Volume749,184
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-2.92
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.83Price Target Upside372.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.3
Revenue Forecast (FY)$2.85M
Bulls Say, Bears Say
Bulls Say
OLC Regulatory ProgressThe assigned FDA inspection is a concrete step toward resolving the manufacturing-related regulatory path. If completed successfully, it could support NDA resubmission and reduce a key barrier to converting OLC development into commercial revenue.
Liquidity PositionThe reported cash balance provides funding capacity for clinical, regulatory, and launch preparation activities over the next several months. Although preliminary and unaudited, this liquidity may reduce immediate financing pressure while OLC advances toward potential approval.
Low LeverageMinimal debt limits interest and repayment burdens, while the recovery from negative equity indicates meaningful balance-sheet repair. This gives Unicycive greater flexibility to fund development and regulatory work without relying heavily on debt financing.
Bears Say
No Commercial RevenueThe absence of recurring product revenue leaves the company dependent on successful OLC development and future commercialization. Persistent large losses also indicate that operating leverage has not yet emerged, limiting financial resilience before approval.
Persistent Cash BurnContinued negative cash generation means the company consumes capital to sustain operations and advance OLC. Even with reported liquidity, ongoing burn increases the likelihood of additional financing before commercial revenue can provide a self-funding operating model.
Dilution And Funding RiskExpanded equity-raising capacity improves access to operating capital but creates material dilution risk if shares are sold. The financing need reflects Unicycive’s dependence on external capital while revenue remains absent and OLC approval is unresolved.
Unicycive Therapeutics News
UNCY FAQ
What was Unicycive Therapeutics’s price range in the past 12 months?
Unicycive Therapeutics lowest stock price was $3.71 and its highest was $8.74 in the past 12 months.
What is Unicycive Therapeutics’s market cap?
Unicycive Therapeutics’s market cap is $143.73M.
When is Unicycive Therapeutics’s upcoming earnings report date?
Unicycive Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 71 days.
How were Unicycive Therapeutics’s earnings last quarter?
Unicycive Therapeutics released its earnings results on Aug 12, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.471 by $0.411.
Is Unicycive Therapeutics overvalued?
According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued.
Does Unicycive Therapeutics pay dividends?
Unicycive Therapeutics does not currently pay dividends.
What is Unicycive Therapeutics’s EPS estimate?
Unicycive Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Unicycive Therapeutics have?
Unicycive Therapeutics has 27,855,257 shares outstanding.
What happened to Unicycive Therapeutics’s price movement after its last earnings report?
Unicycive Therapeutics reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went up 7.8%.
Which hedge fund is a major shareholder of Unicycive Therapeutics?
Currently, no hedge funds are holding shares in UNCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Unicycive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.83 (372.27% Upside)
$25.83 (372.27% Upside)
Blogger Sentiment
Bullish
UNCY Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 263.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
140.14%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Unicycive Therapeutics
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
UNCY Stock 12 Month Forecast
Average Price Target
$25.83
▲(372.27% Upside)
Technical Analysis
Ownership Overview
9.85%
Insiders
3.56% Mutual Funds
20.78% Other Institutional Investors
57.12% Public Companies and Individual Investors